Survey on Sildenafil, Tadalafil, and Vardenafil Concentrations in Food Supplements for Erectile Dysfunction
- PMID: 35855809
- PMCID: PMC9288292
- DOI: 10.1155/2022/3950190
Survey on Sildenafil, Tadalafil, and Vardenafil Concentrations in Food Supplements for Erectile Dysfunction
Abstract
The aim of the study was to analyze the presence of undeclared sildenafil, tadalafil, and vardenafil in food supplements (FSs) for erectile dysfunction. The presence of sildenafil, tadalafil, and vardenafil was determined using the generated ultraviolet (UV)-spectra and mass-spectrometry (MS)-spectra as well as chromatograms produced by the photodiode array (PDA)-detector and ion trap MS-detector. The results were processed by Xcalibur ver. 2.0.7. Fourteen of the 20 analyzed FSs contained undeclared ingredients. Sildenafil was present in 12 of them. Many violations and discrepancies between the label information and the real composition of the FS were identified. 70% of the samples contained undeclared ingredients of an erectile dysfunction medicinal product. The quantities varied within broad limits from 2 mg per tablet to 116.55 mg per tablet. Sildenafil was present in amounts exceeding 16.55 mg that is the maximum recommended dose, thus creating risk of overdose. Besides that, food supplements adulterated with sildenafil analogues are a health risk for consumer's health as there is no evidence of modified sildenafil toxicity. All analyzed FSs were claimed to be 100% natural, not provoking side effects. No information for any FS contained indications of age limits or risk for interaction with other FSs or medical products.
Copyright © 2022 Elina Petkova-Gueorguieva et al.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Similar articles
-
Screening and Determination of Synthetic PDE-5 Inhibitors in Adulterated Sexual Enhancement Supplements.Molecules. 2022 Oct 9;27(19):6737. doi: 10.3390/molecules27196737. Molecules. 2022. PMID: 36235271 Free PMC article.
-
Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.J Sex Med. 2020 May;17(5):941-948. doi: 10.1016/j.jsxm.2020.01.027. Epub 2020 Mar 3. J Sex Med. 2020. PMID: 32144034 Free PMC article.
-
The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction.J Sex Med. 2009 Sep;6(9):2547-60. doi: 10.1111/j.1743-6109.2009.01375.x. Epub 2009 Jun 29. J Sex Med. 2009. PMID: 19570039 Clinical Trial.
-
Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges.J Pharm Biomed Anal. 2014 Jan;87:176-90. doi: 10.1016/j.jpba.2013.04.037. Epub 2013 May 6. J Pharm Biomed Anal. 2014. PMID: 23721687 Review.
-
Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction.Expert Opin Pharmacother. 2005 Jan;6(1):75-84. doi: 10.1517/14656566.6.1.75. Expert Opin Pharmacother. 2005. PMID: 15709885 Review.
Cited by
-
Dietary supplements could prevent cardiometabolic syndrome: Are they safe and reliable enough for disease prevention and health promotion?Front Cardiovasc Med. 2023 Mar 22;10:1091327. doi: 10.3389/fcvm.2023.1091327. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37034351 Free PMC article.
-
Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements.Molecules. 2023 May 16;28(10):4116. doi: 10.3390/molecules28104116. Molecules. 2023. PMID: 37241857 Free PMC article.
-
Isolation and identification of a novel vardenafil analogue, propoxy-vardenafil, found as an adulterant in a health supplement.Heliyon. 2023 Jun 14;9(6):e17253. doi: 10.1016/j.heliyon.2023.e17253. eCollection 2023 Jun. Heliyon. 2023. PMID: 37389037 Free PMC article.
References
-
- Moyad M. A., Barada J. H., Lue T. F., Mulhall J. P., Fawzy I., Fawzy A. Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. Urologic Clinics of North America . 2004;31(2):249–257. doi: 10.1016/j.ucl.2004.01.006. - DOI - PubMed
-
- Quilter M., Hodges L., Von Hurst P., Coad B., Coad J. Male sexual function in New Zealand: a population-based cross-sectional survey of the prevalence of erectile dysfunction in men aged 40–70 years. The Journal of Sexual Medicine . 2017;14(7):928–936. doi: 10.1016/j.jsxm.2017.05.011. - DOI - PubMed
LinkOut - more resources
Full Text Sources